Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial
Patients with non-small-cell lung cancer (NSCLC) that is resistant to PD-1 and PD-L1 (PD[L]-1)-targeted therapy have poor outcomes. Studies suggest that radiotherapy could enhance antitumour immunity. Therefore, we investigated the potential benefit of PD-L1 (durvalumab) and CTLA-4 (tremelimumab) in...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Schoenfeld, Jonathan D [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2022 |
|---|
| Umfang: |
13 |
|---|
| Übergeordnetes Werk: |
Enthalten in: My - Citovsky, Vitaly ELSEVIER, 2019, London |
|---|---|
| Übergeordnetes Werk: |
volume:23 ; year:2022 ; number:2 ; pages:279-291 ; extent:13 |
| Links: |
|---|
| DOI / URN: |
10.1016/S1470-2045(21)00658-6 |
|---|
| Katalog-ID: |
ELV056681496 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV056681496 | ||
| 003 | DE-627 | ||
| 005 | 20230624233632.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220205s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/S1470-2045(21)00658-6 |2 doi | |
| 028 | 5 | 2 | |a /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001817.pica |
| 035 | |a (DE-627)ELV056681496 | ||
| 035 | |a (ELSEVIER)S1470-2045(21)00658-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 570 |q VZ |
| 084 | |a BIODIV |q DE-30 |2 fid | ||
| 084 | |a 35.70 |2 bkl | ||
| 084 | |a 42.12 |2 bkl | ||
| 100 | 1 | |a Schoenfeld, Jonathan D |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial |
| 264 | 1 | |c 2022 | |
| 300 | |a 13 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Patients with non-small-cell lung cancer (NSCLC) that is resistant to PD-1 and PD-L1 (PD[L]-1)-targeted therapy have poor outcomes. Studies suggest that radiotherapy could enhance antitumour immunity. Therefore, we investigated the potential benefit of PD-L1 (durvalumab) and CTLA-4 (tremelimumab) inhibition alone or combined with radiotherapy. | ||
| 700 | 1 | |a Giobbie-Hurder, Anita |4 oth | |
| 700 | 1 | |a Ranasinghe, Srinika |4 oth | |
| 700 | 1 | |a Kao, Katrina Z |4 oth | |
| 700 | 1 | |a Lako, Ana |4 oth | |
| 700 | 1 | |a Tsuji, Junko |4 oth | |
| 700 | 1 | |a Liu, Yang |4 oth | |
| 700 | 1 | |a Brennick, Ryan C |4 oth | |
| 700 | 1 | |a Gentzler, Ryan D |4 oth | |
| 700 | 1 | |a Lee, Carrie |4 oth | |
| 700 | 1 | |a Hubbard, Joleen |4 oth | |
| 700 | 1 | |a Arnold, Susanne M |4 oth | |
| 700 | 1 | |a Abbruzzese, James L |4 oth | |
| 700 | 1 | |a Jabbour, Salma K |4 oth | |
| 700 | 1 | |a Uboha, Nataliya V |4 oth | |
| 700 | 1 | |a Stephans, Kevin L |4 oth | |
| 700 | 1 | |a Johnson, Jennifer M |4 oth | |
| 700 | 1 | |a Park, Haeseong |4 oth | |
| 700 | 1 | |a Villaruz, Liza C |4 oth | |
| 700 | 1 | |a Sharon, Elad |4 oth | |
| 700 | 1 | |a Streicher, Howard |4 oth | |
| 700 | 1 | |a Ahmed, Mansoor M |4 oth | |
| 700 | 1 | |a Lyon, Hayley |4 oth | |
| 700 | 1 | |a Cibuskis, Carrie |4 oth | |
| 700 | 1 | |a Lennon, Niall |4 oth | |
| 700 | 1 | |a Jhaveri, Aashna |4 oth | |
| 700 | 1 | |a Yang, Lin |4 oth | |
| 700 | 1 | |a Altreuter, Jennifer |4 oth | |
| 700 | 1 | |a Gunasti, Lauren |4 oth | |
| 700 | 1 | |a Weirather, Jason L |4 oth | |
| 700 | 1 | |a Mak, Raymond H |4 oth | |
| 700 | 1 | |a Awad, Mark M |4 oth | |
| 700 | 1 | |a Rodig, Scott J |4 oth | |
| 700 | 1 | |a Chen, Helen X |4 oth | |
| 700 | 1 | |a Wu, Catherine J |4 oth | |
| 700 | 1 | |a Monjazeb, Arta M |4 oth | |
| 700 | 1 | |a Hodi, F Stephen |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n The Lancet Publ. Group |a Citovsky, Vitaly ELSEVIER |t My |d 2019 |g London |w (DE-627)ELV003173852 |
| 773 | 1 | 8 | |g volume:23 |g year:2022 |g number:2 |g pages:279-291 |g extent:13 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/S1470-2045(21)00658-6 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a FID-BIODIV | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 35.70 |j Biochemie: Allgemeines |q VZ |
| 936 | b | k | |a 42.12 |j Biophysik |q VZ |
| 951 | |a AR | ||
| 952 | |d 23 |j 2022 |e 2 |h 279-291 |g 13 | ||
| author_variant |
j d s jd jds |
|---|---|
| matchkey_str |
schoenfeldjonathandgiobbiehurderanitaran:2022----:uvlmblsrmlmmblnoicmiainihodsohpfatoaerdohrpimtsainnmlcllncnerfatrtpeiupl |
| hierarchy_sort_str |
2022 |
| bklnumber |
35.70 42.12 |
| publishDate |
2022 |
| allfields |
10.1016/S1470-2045(21)00658-6 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001817.pica (DE-627)ELV056681496 (ELSEVIER)S1470-2045(21)00658-6 DE-627 ger DE-627 rakwb eng 570 VZ BIODIV DE-30 fid 35.70 bkl 42.12 bkl Schoenfeld, Jonathan D verfasserin aut Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial 2022 13 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Patients with non-small-cell lung cancer (NSCLC) that is resistant to PD-1 and PD-L1 (PD[L]-1)-targeted therapy have poor outcomes. Studies suggest that radiotherapy could enhance antitumour immunity. Therefore, we investigated the potential benefit of PD-L1 (durvalumab) and CTLA-4 (tremelimumab) inhibition alone or combined with radiotherapy. Giobbie-Hurder, Anita oth Ranasinghe, Srinika oth Kao, Katrina Z oth Lako, Ana oth Tsuji, Junko oth Liu, Yang oth Brennick, Ryan C oth Gentzler, Ryan D oth Lee, Carrie oth Hubbard, Joleen oth Arnold, Susanne M oth Abbruzzese, James L oth Jabbour, Salma K oth Uboha, Nataliya V oth Stephans, Kevin L oth Johnson, Jennifer M oth Park, Haeseong oth Villaruz, Liza C oth Sharon, Elad oth Streicher, Howard oth Ahmed, Mansoor M oth Lyon, Hayley oth Cibuskis, Carrie oth Lennon, Niall oth Jhaveri, Aashna oth Yang, Lin oth Altreuter, Jennifer oth Gunasti, Lauren oth Weirather, Jason L oth Mak, Raymond H oth Awad, Mark M oth Rodig, Scott J oth Chen, Helen X oth Wu, Catherine J oth Monjazeb, Arta M oth Hodi, F Stephen oth Enthalten in The Lancet Publ. Group Citovsky, Vitaly ELSEVIER My 2019 London (DE-627)ELV003173852 volume:23 year:2022 number:2 pages:279-291 extent:13 https://doi.org/10.1016/S1470-2045(21)00658-6 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA 35.70 Biochemie: Allgemeines VZ 42.12 Biophysik VZ AR 23 2022 2 279-291 13 |
| spelling |
10.1016/S1470-2045(21)00658-6 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001817.pica (DE-627)ELV056681496 (ELSEVIER)S1470-2045(21)00658-6 DE-627 ger DE-627 rakwb eng 570 VZ BIODIV DE-30 fid 35.70 bkl 42.12 bkl Schoenfeld, Jonathan D verfasserin aut Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial 2022 13 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Patients with non-small-cell lung cancer (NSCLC) that is resistant to PD-1 and PD-L1 (PD[L]-1)-targeted therapy have poor outcomes. Studies suggest that radiotherapy could enhance antitumour immunity. Therefore, we investigated the potential benefit of PD-L1 (durvalumab) and CTLA-4 (tremelimumab) inhibition alone or combined with radiotherapy. Giobbie-Hurder, Anita oth Ranasinghe, Srinika oth Kao, Katrina Z oth Lako, Ana oth Tsuji, Junko oth Liu, Yang oth Brennick, Ryan C oth Gentzler, Ryan D oth Lee, Carrie oth Hubbard, Joleen oth Arnold, Susanne M oth Abbruzzese, James L oth Jabbour, Salma K oth Uboha, Nataliya V oth Stephans, Kevin L oth Johnson, Jennifer M oth Park, Haeseong oth Villaruz, Liza C oth Sharon, Elad oth Streicher, Howard oth Ahmed, Mansoor M oth Lyon, Hayley oth Cibuskis, Carrie oth Lennon, Niall oth Jhaveri, Aashna oth Yang, Lin oth Altreuter, Jennifer oth Gunasti, Lauren oth Weirather, Jason L oth Mak, Raymond H oth Awad, Mark M oth Rodig, Scott J oth Chen, Helen X oth Wu, Catherine J oth Monjazeb, Arta M oth Hodi, F Stephen oth Enthalten in The Lancet Publ. Group Citovsky, Vitaly ELSEVIER My 2019 London (DE-627)ELV003173852 volume:23 year:2022 number:2 pages:279-291 extent:13 https://doi.org/10.1016/S1470-2045(21)00658-6 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA 35.70 Biochemie: Allgemeines VZ 42.12 Biophysik VZ AR 23 2022 2 279-291 13 |
| allfields_unstemmed |
10.1016/S1470-2045(21)00658-6 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001817.pica (DE-627)ELV056681496 (ELSEVIER)S1470-2045(21)00658-6 DE-627 ger DE-627 rakwb eng 570 VZ BIODIV DE-30 fid 35.70 bkl 42.12 bkl Schoenfeld, Jonathan D verfasserin aut Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial 2022 13 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Patients with non-small-cell lung cancer (NSCLC) that is resistant to PD-1 and PD-L1 (PD[L]-1)-targeted therapy have poor outcomes. Studies suggest that radiotherapy could enhance antitumour immunity. Therefore, we investigated the potential benefit of PD-L1 (durvalumab) and CTLA-4 (tremelimumab) inhibition alone or combined with radiotherapy. Giobbie-Hurder, Anita oth Ranasinghe, Srinika oth Kao, Katrina Z oth Lako, Ana oth Tsuji, Junko oth Liu, Yang oth Brennick, Ryan C oth Gentzler, Ryan D oth Lee, Carrie oth Hubbard, Joleen oth Arnold, Susanne M oth Abbruzzese, James L oth Jabbour, Salma K oth Uboha, Nataliya V oth Stephans, Kevin L oth Johnson, Jennifer M oth Park, Haeseong oth Villaruz, Liza C oth Sharon, Elad oth Streicher, Howard oth Ahmed, Mansoor M oth Lyon, Hayley oth Cibuskis, Carrie oth Lennon, Niall oth Jhaveri, Aashna oth Yang, Lin oth Altreuter, Jennifer oth Gunasti, Lauren oth Weirather, Jason L oth Mak, Raymond H oth Awad, Mark M oth Rodig, Scott J oth Chen, Helen X oth Wu, Catherine J oth Monjazeb, Arta M oth Hodi, F Stephen oth Enthalten in The Lancet Publ. Group Citovsky, Vitaly ELSEVIER My 2019 London (DE-627)ELV003173852 volume:23 year:2022 number:2 pages:279-291 extent:13 https://doi.org/10.1016/S1470-2045(21)00658-6 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA 35.70 Biochemie: Allgemeines VZ 42.12 Biophysik VZ AR 23 2022 2 279-291 13 |
| allfieldsGer |
10.1016/S1470-2045(21)00658-6 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001817.pica (DE-627)ELV056681496 (ELSEVIER)S1470-2045(21)00658-6 DE-627 ger DE-627 rakwb eng 570 VZ BIODIV DE-30 fid 35.70 bkl 42.12 bkl Schoenfeld, Jonathan D verfasserin aut Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial 2022 13 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Patients with non-small-cell lung cancer (NSCLC) that is resistant to PD-1 and PD-L1 (PD[L]-1)-targeted therapy have poor outcomes. Studies suggest that radiotherapy could enhance antitumour immunity. Therefore, we investigated the potential benefit of PD-L1 (durvalumab) and CTLA-4 (tremelimumab) inhibition alone or combined with radiotherapy. Giobbie-Hurder, Anita oth Ranasinghe, Srinika oth Kao, Katrina Z oth Lako, Ana oth Tsuji, Junko oth Liu, Yang oth Brennick, Ryan C oth Gentzler, Ryan D oth Lee, Carrie oth Hubbard, Joleen oth Arnold, Susanne M oth Abbruzzese, James L oth Jabbour, Salma K oth Uboha, Nataliya V oth Stephans, Kevin L oth Johnson, Jennifer M oth Park, Haeseong oth Villaruz, Liza C oth Sharon, Elad oth Streicher, Howard oth Ahmed, Mansoor M oth Lyon, Hayley oth Cibuskis, Carrie oth Lennon, Niall oth Jhaveri, Aashna oth Yang, Lin oth Altreuter, Jennifer oth Gunasti, Lauren oth Weirather, Jason L oth Mak, Raymond H oth Awad, Mark M oth Rodig, Scott J oth Chen, Helen X oth Wu, Catherine J oth Monjazeb, Arta M oth Hodi, F Stephen oth Enthalten in The Lancet Publ. Group Citovsky, Vitaly ELSEVIER My 2019 London (DE-627)ELV003173852 volume:23 year:2022 number:2 pages:279-291 extent:13 https://doi.org/10.1016/S1470-2045(21)00658-6 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA 35.70 Biochemie: Allgemeines VZ 42.12 Biophysik VZ AR 23 2022 2 279-291 13 |
| allfieldsSound |
10.1016/S1470-2045(21)00658-6 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001817.pica (DE-627)ELV056681496 (ELSEVIER)S1470-2045(21)00658-6 DE-627 ger DE-627 rakwb eng 570 VZ BIODIV DE-30 fid 35.70 bkl 42.12 bkl Schoenfeld, Jonathan D verfasserin aut Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial 2022 13 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Patients with non-small-cell lung cancer (NSCLC) that is resistant to PD-1 and PD-L1 (PD[L]-1)-targeted therapy have poor outcomes. Studies suggest that radiotherapy could enhance antitumour immunity. Therefore, we investigated the potential benefit of PD-L1 (durvalumab) and CTLA-4 (tremelimumab) inhibition alone or combined with radiotherapy. Giobbie-Hurder, Anita oth Ranasinghe, Srinika oth Kao, Katrina Z oth Lako, Ana oth Tsuji, Junko oth Liu, Yang oth Brennick, Ryan C oth Gentzler, Ryan D oth Lee, Carrie oth Hubbard, Joleen oth Arnold, Susanne M oth Abbruzzese, James L oth Jabbour, Salma K oth Uboha, Nataliya V oth Stephans, Kevin L oth Johnson, Jennifer M oth Park, Haeseong oth Villaruz, Liza C oth Sharon, Elad oth Streicher, Howard oth Ahmed, Mansoor M oth Lyon, Hayley oth Cibuskis, Carrie oth Lennon, Niall oth Jhaveri, Aashna oth Yang, Lin oth Altreuter, Jennifer oth Gunasti, Lauren oth Weirather, Jason L oth Mak, Raymond H oth Awad, Mark M oth Rodig, Scott J oth Chen, Helen X oth Wu, Catherine J oth Monjazeb, Arta M oth Hodi, F Stephen oth Enthalten in The Lancet Publ. Group Citovsky, Vitaly ELSEVIER My 2019 London (DE-627)ELV003173852 volume:23 year:2022 number:2 pages:279-291 extent:13 https://doi.org/10.1016/S1470-2045(21)00658-6 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA 35.70 Biochemie: Allgemeines VZ 42.12 Biophysik VZ AR 23 2022 2 279-291 13 |
| language |
English |
| source |
Enthalten in My London volume:23 year:2022 number:2 pages:279-291 extent:13 |
| sourceStr |
Enthalten in My London volume:23 year:2022 number:2 pages:279-291 extent:13 |
| format_phy_str_mv |
Article |
| bklname |
Biochemie: Allgemeines Biophysik |
| institution |
findex.gbv.de |
| dewey-raw |
570 |
| isfreeaccess_bool |
false |
| container_title |
My |
| authorswithroles_txt_mv |
Schoenfeld, Jonathan D @@aut@@ Giobbie-Hurder, Anita @@oth@@ Ranasinghe, Srinika @@oth@@ Kao, Katrina Z @@oth@@ Lako, Ana @@oth@@ Tsuji, Junko @@oth@@ Liu, Yang @@oth@@ Brennick, Ryan C @@oth@@ Gentzler, Ryan D @@oth@@ Lee, Carrie @@oth@@ Hubbard, Joleen @@oth@@ Arnold, Susanne M @@oth@@ Abbruzzese, James L @@oth@@ Jabbour, Salma K @@oth@@ Uboha, Nataliya V @@oth@@ Stephans, Kevin L @@oth@@ Johnson, Jennifer M @@oth@@ Park, Haeseong @@oth@@ Villaruz, Liza C @@oth@@ Sharon, Elad @@oth@@ Streicher, Howard @@oth@@ Ahmed, Mansoor M @@oth@@ Lyon, Hayley @@oth@@ Cibuskis, Carrie @@oth@@ Lennon, Niall @@oth@@ Jhaveri, Aashna @@oth@@ Yang, Lin @@oth@@ Altreuter, Jennifer @@oth@@ Gunasti, Lauren @@oth@@ Weirather, Jason L @@oth@@ Mak, Raymond H @@oth@@ Awad, Mark M @@oth@@ Rodig, Scott J @@oth@@ Chen, Helen X @@oth@@ Wu, Catherine J @@oth@@ Monjazeb, Arta M @@oth@@ Hodi, F Stephen @@oth@@ |
| publishDateDaySort_date |
2022-01-01T00:00:00Z |
| hierarchy_top_id |
ELV003173852 |
| dewey-sort |
3570 |
| id |
ELV056681496 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV056681496</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624233632.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">220205s2022 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/S1470-2045(21)00658-6</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001817.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV056681496</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1470-2045(21)00658-6</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">570</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">BIODIV</subfield><subfield code="q">DE-30</subfield><subfield code="2">fid</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">35.70</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">42.12</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Schoenfeld, Jonathan D</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">13</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Patients with non-small-cell lung cancer (NSCLC) that is resistant to PD-1 and PD-L1 (PD[L]-1)-targeted therapy have poor outcomes. Studies suggest that radiotherapy could enhance antitumour immunity. Therefore, we investigated the potential benefit of PD-L1 (durvalumab) and CTLA-4 (tremelimumab) inhibition alone or combined with radiotherapy.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Giobbie-Hurder, Anita</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ranasinghe, Srinika</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kao, Katrina Z</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lako, Ana</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tsuji, Junko</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Liu, Yang</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Brennick, Ryan C</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gentzler, Ryan D</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lee, Carrie</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hubbard, Joleen</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Arnold, Susanne M</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Abbruzzese, James L</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Jabbour, Salma K</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Uboha, Nataliya V</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Stephans, Kevin L</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Johnson, Jennifer M</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Park, Haeseong</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Villaruz, Liza C</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sharon, Elad</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Streicher, Howard</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ahmed, Mansoor M</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lyon, Hayley</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Cibuskis, Carrie</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lennon, Niall</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Jhaveri, Aashna</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yang, Lin</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Altreuter, Jennifer</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gunasti, Lauren</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Weirather, Jason L</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mak, Raymond H</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Awad, Mark M</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rodig, Scott J</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chen, Helen X</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wu, Catherine J</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Monjazeb, Arta M</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hodi, F Stephen</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">The Lancet Publ. Group</subfield><subfield code="a">Citovsky, Vitaly ELSEVIER</subfield><subfield code="t">My</subfield><subfield code="d">2019</subfield><subfield code="g">London</subfield><subfield code="w">(DE-627)ELV003173852</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:23</subfield><subfield code="g">year:2022</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:279-291</subfield><subfield code="g">extent:13</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/S1470-2045(21)00658-6</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">FID-BIODIV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">35.70</subfield><subfield code="j">Biochemie: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">42.12</subfield><subfield code="j">Biophysik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">23</subfield><subfield code="j">2022</subfield><subfield code="e">2</subfield><subfield code="h">279-291</subfield><subfield code="g">13</subfield></datafield></record></collection>
|
| author |
Schoenfeld, Jonathan D |
| spellingShingle |
Schoenfeld, Jonathan D ddc 570 fid BIODIV bkl 35.70 bkl 42.12 Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial |
| authorStr |
Schoenfeld, Jonathan D |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV003173852 |
| format |
electronic Article |
| dewey-ones |
570 - Life sciences; biology |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
570 VZ BIODIV DE-30 fid 35.70 bkl 42.12 bkl Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial |
| topic |
ddc 570 fid BIODIV bkl 35.70 bkl 42.12 |
| topic_unstemmed |
ddc 570 fid BIODIV bkl 35.70 bkl 42.12 |
| topic_browse |
ddc 570 fid BIODIV bkl 35.70 bkl 42.12 |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
a g h agh s r sr k z k kz kzk a l al j t jt y l yl r c b rc rcb r d g rd rdg c l cl j h jh s m a sm sma j l a jl jla s k j sk skj n v u nv nvu k l s kl kls j m j jm jmj h p hp l c v lc lcv e s es h s hs m m a mm mma h l hl c c cc n l nl a j aj l y ly j a ja l g lg j l w jl jlw r h m rh rhm m m a mm mma s j r sj sjr h x c hx hxc c j w cj cjw a m m am amm f s h fs fsh |
| hierarchy_parent_title |
My |
| hierarchy_parent_id |
ELV003173852 |
| dewey-tens |
570 - Life sciences; biology |
| hierarchy_top_title |
My |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV003173852 |
| title |
Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial |
| ctrlnum |
(DE-627)ELV056681496 (ELSEVIER)S1470-2045(21)00658-6 |
| title_full |
Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial |
| author_sort |
Schoenfeld, Jonathan D |
| journal |
My |
| journalStr |
My |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
500 - Science |
| recordtype |
marc |
| publishDateSort |
2022 |
| contenttype_str_mv |
zzz |
| container_start_page |
279 |
| author_browse |
Schoenfeld, Jonathan D |
| container_volume |
23 |
| physical |
13 |
| class |
570 VZ BIODIV DE-30 fid 35.70 bkl 42.12 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Schoenfeld, Jonathan D |
| doi_str_mv |
10.1016/S1470-2045(21)00658-6 |
| dewey-full |
570 |
| title_sort |
durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous pd(l)-1 therapy: an open-label, multicentre, randomised, phase 2 trial |
| title_auth |
Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial |
| abstract |
Patients with non-small-cell lung cancer (NSCLC) that is resistant to PD-1 and PD-L1 (PD[L]-1)-targeted therapy have poor outcomes. Studies suggest that radiotherapy could enhance antitumour immunity. Therefore, we investigated the potential benefit of PD-L1 (durvalumab) and CTLA-4 (tremelimumab) inhibition alone or combined with radiotherapy. |
| abstractGer |
Patients with non-small-cell lung cancer (NSCLC) that is resistant to PD-1 and PD-L1 (PD[L]-1)-targeted therapy have poor outcomes. Studies suggest that radiotherapy could enhance antitumour immunity. Therefore, we investigated the potential benefit of PD-L1 (durvalumab) and CTLA-4 (tremelimumab) inhibition alone or combined with radiotherapy. |
| abstract_unstemmed |
Patients with non-small-cell lung cancer (NSCLC) that is resistant to PD-1 and PD-L1 (PD[L]-1)-targeted therapy have poor outcomes. Studies suggest that radiotherapy could enhance antitumour immunity. Therefore, we investigated the potential benefit of PD-L1 (durvalumab) and CTLA-4 (tremelimumab) inhibition alone or combined with radiotherapy. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA |
| container_issue |
2 |
| title_short |
Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial |
| url |
https://doi.org/10.1016/S1470-2045(21)00658-6 |
| remote_bool |
true |
| author2 |
Giobbie-Hurder, Anita Ranasinghe, Srinika Kao, Katrina Z Lako, Ana Tsuji, Junko Liu, Yang Brennick, Ryan C Gentzler, Ryan D Lee, Carrie Hubbard, Joleen Arnold, Susanne M Abbruzzese, James L Jabbour, Salma K Uboha, Nataliya V Stephans, Kevin L Johnson, Jennifer M Park, Haeseong Villaruz, Liza C Sharon, Elad Streicher, Howard Ahmed, Mansoor M Lyon, Hayley Cibuskis, Carrie Lennon, Niall Jhaveri, Aashna Yang, Lin Altreuter, Jennifer Gunasti, Lauren Weirather, Jason L Mak, Raymond H Awad, Mark M Rodig, Scott J Chen, Helen X Wu, Catherine J Monjazeb, Arta M Hodi, F Stephen |
| author2Str |
Giobbie-Hurder, Anita Ranasinghe, Srinika Kao, Katrina Z Lako, Ana Tsuji, Junko Liu, Yang Brennick, Ryan C Gentzler, Ryan D Lee, Carrie Hubbard, Joleen Arnold, Susanne M Abbruzzese, James L Jabbour, Salma K Uboha, Nataliya V Stephans, Kevin L Johnson, Jennifer M Park, Haeseong Villaruz, Liza C Sharon, Elad Streicher, Howard Ahmed, Mansoor M Lyon, Hayley Cibuskis, Carrie Lennon, Niall Jhaveri, Aashna Yang, Lin Altreuter, Jennifer Gunasti, Lauren Weirather, Jason L Mak, Raymond H Awad, Mark M Rodig, Scott J Chen, Helen X Wu, Catherine J Monjazeb, Arta M Hodi, F Stephen |
| ppnlink |
ELV003173852 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth |
| doi_str |
10.1016/S1470-2045(21)00658-6 |
| up_date |
2024-07-06T21:05:53.794Z |
| _version_ |
1803865244351594496 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV056681496</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624233632.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">220205s2022 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/S1470-2045(21)00658-6</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001817.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV056681496</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1470-2045(21)00658-6</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">570</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">BIODIV</subfield><subfield code="q">DE-30</subfield><subfield code="2">fid</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">35.70</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">42.12</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Schoenfeld, Jonathan D</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">13</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Patients with non-small-cell lung cancer (NSCLC) that is resistant to PD-1 and PD-L1 (PD[L]-1)-targeted therapy have poor outcomes. Studies suggest that radiotherapy could enhance antitumour immunity. Therefore, we investigated the potential benefit of PD-L1 (durvalumab) and CTLA-4 (tremelimumab) inhibition alone or combined with radiotherapy.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Giobbie-Hurder, Anita</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ranasinghe, Srinika</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kao, Katrina Z</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lako, Ana</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tsuji, Junko</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Liu, Yang</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Brennick, Ryan C</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gentzler, Ryan D</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lee, Carrie</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hubbard, Joleen</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Arnold, Susanne M</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Abbruzzese, James L</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Jabbour, Salma K</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Uboha, Nataliya V</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Stephans, Kevin L</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Johnson, Jennifer M</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Park, Haeseong</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Villaruz, Liza C</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sharon, Elad</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Streicher, Howard</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ahmed, Mansoor M</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lyon, Hayley</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Cibuskis, Carrie</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lennon, Niall</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Jhaveri, Aashna</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yang, Lin</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Altreuter, Jennifer</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gunasti, Lauren</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Weirather, Jason L</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mak, Raymond H</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Awad, Mark M</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rodig, Scott J</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chen, Helen X</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wu, Catherine J</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Monjazeb, Arta M</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hodi, F Stephen</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">The Lancet Publ. Group</subfield><subfield code="a">Citovsky, Vitaly ELSEVIER</subfield><subfield code="t">My</subfield><subfield code="d">2019</subfield><subfield code="g">London</subfield><subfield code="w">(DE-627)ELV003173852</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:23</subfield><subfield code="g">year:2022</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:279-291</subfield><subfield code="g">extent:13</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/S1470-2045(21)00658-6</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">FID-BIODIV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">35.70</subfield><subfield code="j">Biochemie: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">42.12</subfield><subfield code="j">Biophysik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">23</subfield><subfield code="j">2022</subfield><subfield code="e">2</subfield><subfield code="h">279-291</subfield><subfield code="g">13</subfield></datafield></record></collection>
|
| score |
7.399349 |